Nivolumab/brentuximab vedotin in R/R HL: good CMR rates Presented ByProf. Christine Mauz-Körholz, Justus-Liebig-Universität Gießen, Germany TrialPhase 2, Checkmate 744 ConferenceEHA 2020 28 August, 2020 12:09